Viewer recommended! Whiteboard style discussion on a randomized, double blinded, placebo control trial published in the New England Journal of Medicine looking at the use of hydroxychloroquine as prophylaxis in those with a high risk exposure to COVID-19. In their supplementary material, they also look at Zinc with the Hydroxychloroquine for post-exposure prophylaxis. They enrolled over 800 patients in the USA and Canada. They found no difference in incidence of COVID-19 in the HCQ versus placebo group. They did see an increased incidence of gastrointestinal side effects in those taking the HCQ. Check out the video for all the details!
Link to article:
Link to Supplementals with Zn data:
There will be a running series of videos using the most up to date information on COVID-19, but this is an evolving field and new videos may come out that contradict that previous information. That is okay and is the nature of a fast paced and evolving clinical scenario. Stick with us as we work to unveil the intricacies of COVID-19, it’s clinical significance, and the societal implications. *****This is strictly educational and not to be mistaken as clinical recommendations, please verify all information with accepted guidelines and practice patterns.****
DISCLAIMER
THIS VIDEO DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read, watched, or listened to on this video, or any other videos, reports, texts tweets or other sources.
